About Kaleido Biosciences
Kaleido Biosciences is a company based in Cambridge (United States) founded in 2015. It operates as a B2B. Kaleido Biosciences has raised $101 million across 2 funding rounds from investors including Fidelity Investments, Flagship Pioneering and Invus. The company has 81 employees. Kaleido Biosciences operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, Kriya Therapeutics, Vir Biotechnology and Biological E, among others.
- Headquarter Cambridge, United States
- Employees 81
- SectorsHealthcare
- Website kaleido.com
- Social X
- Legal Name Kaleido Biosciences, Inc.
- Annual Revenue$1.1 M (USD)13.23as on Dec 31, 2021
- Net Profit-$90.29 M (USD)-10.62as on Dec 31, 2021
- EBITDA-$85.31 M (USD)-10.72as on Dec 31, 2021
- Total Equity Funding$101M (USD)
in 2 rounds
- Latest Funding Round$101M (USD), Series C
Jun 2018
- InvestorsFidelity Investments
& 5 more
- Employee Count81
Funding Insights of Kaleido Biosciences
Kaleido Biosciences has successfully raised a total of $101M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $101 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $101M
- Total Rounds 2
- Last Round Series C — $101M
- Investors Count 6
All 2 funding rounds of Kaleido Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $101M | Series C | – | Invus, Rock Springs Capital | |
| Jun 2017 | – | Series B | – | Flagship Pioneering, Mike Bonney | – |
6 investors in total: 5 institutional and 1 angel.
Investors in Kaleido Biosciences
Kaleido Biosciences has secured backing from 6 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, Flagship Pioneering and Invus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Long-term value is created through diversified sovereign wealth investments. | – | adia.ae | Abu Dhabi, United Arab Emirates | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
MB Mike Bonney | - | – | unknown_4e304084a81245598 | - |
Investor details for Kaleido Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Kaleido Biosciences
Kaleido Biosciences is a publicly listed company on the OTC with ticker symbol KLDO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Feb 2019
- Listed onOTC: KLDO
- Listed entityKaleido Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS4833471000
- Share price$0.00 · 2026-10-09
- Market capitalisation$4,262.00
- Volume (last session)11,167
Financials of Kaleido Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2021 | $1.1M | -$90.3M | -$85.3M |
| 2020 | $975,000 | -$81.6M | -$77.0M |
Detailed financial statements for Kaleido Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kaleido Biosciences
4 dated milestones of Kaleido Biosciences across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Kaleido Biosciences is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $101.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Kaleido Biosciences
Kaleido Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, Kriya Therapeutics, Vir Biotechnology and Biological E, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| evelobio.com | 2015 | Cambridge, United States | $166.5M | 117 | Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| dermbiont.com | 2015 | Melrose, United States | $78.91M | 14 | Microbial therapeutics for skin diseases are developed. |
Detailed competitors of Kaleido Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kaleido Biosciences
Complete news archive for Kaleido Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Kaleido Biosciences
10 companies that operate in the same segment as Kaleido Biosciences (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kaleido Biosciences
Kaleido Biosciences was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Kaleido Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Kaleido Biosciences is a funded company, having raised a total of $101M across 2 funding rounds to date.
Kaleido Biosciences has 81 employees.
Annual revenue of Kaleido Biosciences is $1.1M as on Dec 31, 2021.
Kaleido Biosciences, backed by 101000000.0 from Invus, Rock Springs Capital, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity Investments, Mike Bonney, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and microbiome therapies. Develops innovative microbiome-based therapies for treating inflammatory conditions. Driving innovation, growth, and excellence in its industry sectors.
Kaleido Biosciences's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Yes, Kaleido Biosciences is publicly traded on OTC under the ticker symbol KLDO.
Kaleido Biosciences has 6 investors. Key investors include Fidelity Investments, Flagship Pioneering, Invus, Rock Springs Capital, and Abu Dhabi Investment Authority.
Kaleido Biosciences operates through Kaleido Biosciences, Inc..